Antiviral therapy using thiazine and xanthene dyes

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/54 (2006.01) A61K 31/35 (2006.01) C12N 7/04 (2006.01) A61M 1/36 (2006.01)

Patent

CA 2055463

A method for using thiazine and xanthene dyes to selectively inactivate or inhibit intracellular replication of specific viruses, especially human immunodeficiency virus. Examples of useful xanthine dyes are rose bengal and eosin Y. A preferred thiazine dye is methylene blue. The dyes interfere with transcription and translation of viral nucleic acid. Light penetrating the skin to the capillaries at the surface can be used to enhance the activity of the dye.

Méthode d'utilisation des colorants de thiazine et de xanthène pour inactiver ou inhiber de façon sélective la reproduction intracellulaire de certains virus, particulièrement les virus de l'immunodéficience humaine. Le rose Bengale et l'éosine Y sont des exemples de colorants efficaces de xanthène. Le bleu de méthylène est un colorant de thiazine de choix. Les colorants entravent la transcription et la traduction de l'acide nucléique viral. La lumière qui pénètre la peau vers les capillaires à la surface peut servir à augmenter l'activité du colorant.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Antiviral therapy using thiazine and xanthene dyes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral therapy using thiazine and xanthene dyes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral therapy using thiazine and xanthene dyes will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1960188

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.